Pneumonia Market Set to Witness Robust Growth During the Forecast Period (2026-2036), Driven by Advancing Therapeutics and Rising Disease Burden | DelveInsight

The growth of the pneumonia market is expected to be primarily driven by an expanding patient population and advancements in diagnostic methods. Additionally, the expected launch of emerging therapies such as Tosatoxumab (AR-301) (Aridis Pharmaceuticals), AON-D21 (Aptarion Biotech),...